Merck (MRK) announced significant positive Phase 3 trial results for two distinct endometrial cancer treatments, signaling strong pipeline momentum and potential market expansion .
- Sacituzumab Tirumotecan (sac-TMT): Investigational TROP2-directed ADC reduced death risk by 32% and disease progression/death risk by 41% vs. chemotherapy in advanced/recurrent patients. FDA has accepted for priority review .
- Keytruda (pembrolizumab): Monotherapy reduced disease progression/death risk by 43% vs. chemotherapy in dMMR advanced/recurrent patients. Favorable OS trend observed .
These clinical wins underscore Merck's leadership in oncology and could drive substantial revenue growth in the coming years.
Merck drug cuts death risk by 32% in endometrial cancer trial
INVESTING.COMOct 26, 3:33 PM UTC
Merck’s Keytruda cuts disease progression risk in endometrial cancer
INVESTING.COMOct 26, 3:42 PM UTC
1